Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer

NCT02154646 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT02154646
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02154646 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1b Study of LY2157299 in Combination With Gemcitabine in Patients With Advanced or Metastatic Unresectable Pancreatic Cancer
Lead sponsor
Eli Lilly and Company
Phase
Phase 1
Overall status
Completed
Start date
May 31, 2014
Completion date
July 31, 2015
Enrollment
6 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic neoplasms